| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The primary target of 1-methyl-2-pentyl-4(1H)-quinolinone is Plasmodium falciparum type II NADH dehydrogenase (PfNDH2). The compound is a specific inhibitor of PfNDH2. By inhibiting this enzyme, the compound disrupts the parasite's energy metabolism. 1-Methyl-2-pentyl-4(1H)-quinolinone significantly inhibits malaria parasite development in the mosquito stage. The compound has low toxicity.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated the biological activities of 1-methyl-2-pentyl-4(1H)-quinolinone. The compound has antibacterial activity. It has anticancer bioactivity. The compound inhibits PfNDH2. These activities support its potential for further investigation.
|
| ln Vivo |
In vivo studies have shown that 1-methyl-2-pentyl-4(1H)-quinolinone significantly inhibits the development of malaria parasites in the mosquito stage. The compound has low toxicity. It has potential for blocking malaria transmission. Specific in vivo data have been reported in the literature.
|
| Enzyme Assay |
For PfNDH2 inhibition assays, recombinant PfNDH2 enzyme is incubated with a substrate in the presence of 1-methyl-2-pentyl-4(1H)-quinolinone. Enzyme activity is measured, and IC₅₀ values are calculated. For antibacterial assays, standard broth microdilution methods are used. For anticancer assays, cancer cell lines are treated with the compound.
|
| Cell Assay |
For in vitro cell-based studies, cancer cell lines or bacterial cells are cultured in appropriate media and treated with serial dilutions of 1-methyl-2-pentyl-4(1H)-quinolinone. Cell viability is assessed using MTT or other assays. For antimalarial studies, P. falciparum parasites are cultured and treated with the compound.
|
| Animal Protocol |
In vivo animal studies for 1-methyl-2-pentyl-4(1H)-quinolinone have been conducted in models of malaria transmission. The compound's effects on mosquito-stage parasite development have been evaluated. Standard protocols for in vivo efficacy studies are described in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 1-methyl-2-pentyl-4(1H)-quinolinone have not been extensively characterized. As a quinolone alkaloid with a molecular weight of 229.32 g/mol, it is expected to have reasonable membrane permeability. The compound has low toxicity. Specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for 1-methyl-2-pentyl-4(1H)-quinolinone indicate that the compound has low toxicity. As a natural alkaloid, it may have a favorable safety profile. However, systematic toxicological studies have not been extensively published. The compound is for research use only.
|
| References | |
| Additional Infomation |
1-Methyl-2-pentyl-4(1H)-quinolinone is a research compound used in studies of quinolone alkaloids and their biological activities. It is a specific PfNDH2 inhibitor with potential for blocking malaria transmission. The compound also has antibacterial and anticancer activities. No clinical trials or therapeutic applications have been reported.
|
| Molecular Formula |
C15H19NO
|
|---|---|
| Molecular Weight |
229.32
|
| Exact Mass |
229.146
|
| CAS # |
22048-98-2
|
| PubChem CID |
21709636
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
332.1±42.0 °C at 760 mmHg
|
| Flash Point |
115.3±17.3 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.539
|
| LogP |
3.97
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
308
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C([H])=C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])N(C([H])([H])[H])C2=C([H])C([H])=C([H])C([H])=C21
|
| InChi Key |
CHULATXGEVFYAJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H19NO/c1-3-4-5-8-12-11-15(17)13-9-6-7-10-14(13)16(12)2/h6-7,9-11H,3-5,8H2,1-2H3
|
| Chemical Name |
1-methyl-2-pentylquinolin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3607 mL | 21.8036 mL | 43.6072 mL | |
| 5 mM | 0.8721 mL | 4.3607 mL | 8.7214 mL | |
| 10 mM | 0.4361 mL | 2.1804 mL | 4.3607 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
